Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antiphospholipid Syndrome | 5 | 2019 | 533 | 0.92 | Why? |
| Fatty Liver | 1 | 2021 | 299 | 0.66 | Why? |
| T-Lymphocytes, Regulatory | 2 | 2019 | 698 | 0.58 | Why? |
| Th17 Cells | 1 | 2019 | 657 | 0.52 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2019 | 1380 | 0.42 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.38 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.36 | Why? |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2020 | 235 | 0.30 | Why? |
| Antibodies, Antiphospholipid | 3 | 2017 | 519 | 0.27 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.26 | Why? |
| HLA Antigens | 3 | 2018 | 830 | 0.26 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.24 | Why? |
| Graft Rejection | 3 | 2018 | 1766 | 0.24 | Why? |
| CD40 Ligand | 1 | 2021 | 121 | 0.22 | Why? |
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2020 | 140 | 0.20 | Why? |
| Interleukin-2 | 1 | 2021 | 443 | 0.19 | Why? |
| Nucleoproteins | 1 | 2021 | 223 | 0.19 | Why? |
| Cryoglobulinemia | 1 | 2020 | 144 | 0.19 | Why? |
| Basophils | 1 | 2019 | 179 | 0.19 | Why? |
| Risperidone | 1 | 2018 | 55 | 0.18 | Why? |
| Uridine Monophosphate | 1 | 2018 | 41 | 0.18 | Why? |
| Nephritis, Interstitial | 1 | 2019 | 83 | 0.18 | Why? |
| Delayed Graft Function | 1 | 2018 | 52 | 0.18 | Why? |
| Aripiprazole | 1 | 2018 | 60 | 0.18 | Why? |
| IgG Deficiency | 1 | 2017 | 22 | 0.18 | Why? |
| S100 Calcium Binding Protein beta Subunit | 1 | 2017 | 63 | 0.17 | Why? |
| Paraneoplastic Syndromes | 1 | 2017 | 28 | 0.17 | Why? |
| Graft Survival | 2 | 2018 | 587 | 0.17 | Why? |
| Psychotic Disorders | 2 | 2018 | 924 | 0.17 | Why? |
| Fluorenes | 1 | 2018 | 101 | 0.17 | Why? |
| Polysaccharides, Bacterial | 1 | 2017 | 59 | 0.17 | Why? |
| Flow Cytometry | 3 | 2021 | 2393 | 0.17 | Why? |
| Isoantibodies | 1 | 2017 | 134 | 0.16 | Why? |
| B-Lymphocyte Subsets | 1 | 2018 | 372 | 0.15 | Why? |
| Benzimidazoles | 1 | 2018 | 275 | 0.15 | Why? |
| Climate | 1 | 2020 | 557 | 0.15 | Why? |
| Weather | 1 | 2020 | 581 | 0.14 | Why? |
| Glomerulonephritis | 1 | 2017 | 226 | 0.14 | Why? |
| Immunoglobulin G | 6 | 2021 | 21571 | 0.14 | Why? |
| Vitamin D | 2 | 2021 | 2904 | 0.13 | Why? |
| Kidney Transplantation | 3 | 2018 | 5397 | 0.13 | Why? |
| Spain | 9 | 2021 | 15545 | 0.13 | Why? |
| Immunologic Deficiency Syndromes | 1 | 2017 | 368 | 0.13 | Why? |
| Antibodies, Bacterial | 1 | 2017 | 510 | 0.13 | Why? |
| Weight Gain | 1 | 2018 | 552 | 0.12 | Why? |
| Brain Injuries | 1 | 2017 | 374 | 0.12 | Why? |
| Disease Eradication | 1 | 2018 | 581 | 0.11 | Why? |
| Overweight | 1 | 2018 | 916 | 0.11 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2019 | 1387 | 0.11 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.11 | Why? |
| Chilblains | 1 | 2020 | 1156 | 0.10 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.10 | Why? |
| Antipsychotic Agents | 1 | 2018 | 887 | 0.10 | Why? |
| Immunity, Humoral | 2 | 2021 | 4849 | 0.10 | Why? |
| Peptides | 1 | 2021 | 2513 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.09 | Why? |
| Complement C1q | 2 | 2018 | 31 | 0.09 | Why? |
| Prisons | 1 | 2018 | 980 | 0.09 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.09 | Why? |
| Immunoassay | 2 | 2021 | 4485 | 0.09 | Why? |
| Environmental Exposure | 1 | 2018 | 1558 | 0.08 | Why? |
| Health Status | 1 | 2020 | 3259 | 0.08 | Why? |
| Liver | 1 | 2021 | 4007 | 0.08 | Why? |
| Epitopes | 1 | 2018 | 4113 | 0.08 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4545 | 0.08 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.07 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.07 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.07 | Why? |
| Humans | 32 | 2021 | 930598 | 0.07 | Why? |
| Follow-Up Studies | 6 | 2018 | 17020 | 0.07 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.07 | Why? |
| Adult | 17 | 2021 | 244371 | 0.07 | Why? |
| Kidney | 1 | 2018 | 3648 | 0.06 | Why? |
| Female | 21 | 2021 | 380317 | 0.06 | Why? |
| Thrombocytopenia | 1 | 2017 | 2093 | 0.06 | Why? |
| Immunologic Memory | 1 | 2015 | 3362 | 0.06 | Why? |
| Immunoglobulin A | 3 | 2021 | 3567 | 0.06 | Why? |
| Biomarkers | 5 | 2018 | 23361 | 0.06 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.06 | Why? |
| Fibrinogens, Abnormal | 1 | 2020 | 12 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Myeloblastin | 1 | 2020 | 57 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2017 | 3222 | 0.05 | Why? |
| Male | 17 | 2021 | 367725 | 0.05 | Why? |
| Cryoglobulins | 1 | 2020 | 51 | 0.05 | Why? |
| Thrombosis | 3 | 2018 | 7504 | 0.05 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.05 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.05 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2021 | 6166 | 0.05 | Why? |
| Peroxidase | 1 | 2020 | 207 | 0.05 | Why? |
| Calibration | 1 | 2020 | 307 | 0.05 | Why? |
| Liver Transplantation | 1 | 2015 | 2864 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2018 | 6153 | 0.05 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.05 | Why? |
| Dysgammaglobulinemia | 1 | 2017 | 1 | 0.05 | Why? |
| Heparan Sulfate Proteoglycans | 1 | 2018 | 49 | 0.05 | Why? |
| Reflex | 1 | 2017 | 22 | 0.05 | Why? |
| Pupil | 1 | 2017 | 22 | 0.05 | Why? |
| Prospective Studies | 6 | 2020 | 43301 | 0.05 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.05 | Why? |
| Glasgow Outcome Scale | 1 | 2017 | 56 | 0.05 | Why? |
| beta 2-Glycoprotein I | 1 | 2018 | 92 | 0.05 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.05 | Why? |
| B-Cell Activating Factor | 1 | 2018 | 36 | 0.05 | Why? |
| Likelihood Functions | 1 | 2020 | 719 | 0.04 | Why? |
| Hepatitis C Antibodies | 1 | 2018 | 120 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Double-Blind Method | 2 | 2020 | 5988 | 0.04 | Why? |
| Young Adult | 8 | 2021 | 93724 | 0.04 | Why? |
| Glasgow Coma Scale | 1 | 2017 | 249 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.04 | Why? |
| Reference Standards | 1 | 2020 | 1163 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Histocompatibility Testing | 1 | 2017 | 219 | 0.04 | Why? |
| Data Interpretation, Statistical | 1 | 2020 | 657 | 0.04 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.04 | Why? |
| Brain Death | 1 | 2017 | 146 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Chemoprevention | 1 | 2020 | 585 | 0.04 | Why? |
| Kidney Function Tests | 1 | 2017 | 520 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Common Variable Immunodeficiency | 1 | 2017 | 195 | 0.04 | Why? |
| Aged | 10 | 2021 | 215776 | 0.04 | Why? |
| Antibody-Dependent Cell Cytotoxicity | 1 | 2017 | 349 | 0.04 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.03 | Why? |
| Prognosis | 4 | 2021 | 32490 | 0.03 | Why? |
| Acute Disease | 2 | 2018 | 6029 | 0.03 | Why? |
| Allografts | 1 | 2017 | 761 | 0.03 | Why? |
| Linear Models | 1 | 2020 | 1914 | 0.03 | Why? |
| Sofosbuvir | 1 | 2018 | 518 | 0.03 | Why? |
| Social Class | 1 | 2021 | 1360 | 0.03 | Why? |
| Milk, Human | 1 | 2021 | 956 | 0.03 | Why? |
| Sex Characteristics | 1 | 2020 | 1120 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.03 | Why? |
| Logistic Models | 2 | 2017 | 9089 | 0.03 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.03 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.03 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.03 | Why? |
| Feasibility Studies | 1 | 2021 | 3467 | 0.03 | Why? |
| Biopsy | 1 | 2020 | 2811 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2017 | 1262 | 0.03 | Why? |
| Ultraviolet Rays | 1 | 2020 | 1272 | 0.03 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Breast Feeding | 1 | 2021 | 1585 | 0.03 | Why? |
| Complement Activation | 1 | 2017 | 949 | 0.03 | Why? |
| Antigens, CD | 1 | 2015 | 984 | 0.03 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.02 | Why? |
| Prisoners | 1 | 2018 | 738 | 0.02 | Why? |
| Immunization | 1 | 2018 | 2019 | 0.02 | Why? |
| Intracranial Hemorrhages | 1 | 2017 | 1170 | 0.02 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.02 | Why? |
| Hepacivirus | 1 | 2018 | 1509 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Skin | 1 | 2020 | 2096 | 0.02 | Why? |
| Tissue Donors | 1 | 2017 | 1679 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Pregnant Women | 1 | 2021 | 2535 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Vitamin D Deficiency | 1 | 2021 | 1782 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Pregnancy | 2 | 2021 | 23879 | 0.02 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2017 | 1671 | 0.02 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Pregnancy Complications | 1 | 2017 | 1388 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Heparin | 1 | 2017 | 2600 | 0.02 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.02 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.02 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.02 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.01 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Interleukin-6 | 1 | 2018 | 7522 | 0.01 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Viral Load | 1 | 2018 | 15850 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Disease Progression | 1 | 2015 | 13580 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Anticoagulants | 1 | 2017 | 9563 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2017 | 88759 | 0.01 | Why? |